<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">There may be a role for the Janus kinase inhibitor baricitinib in the treatment of acute COVID-19 respiratory disease. Viruses infect cells by means of endocytosis, and AP2-associated protein kinase 1 (AAK1) is a key regulator of endocytosis. Baricitinib seems to inhibit AAK1 and binding cyclin G-associated kinase (GAK), another regulator of endocytosis, thus blocking viral entry [
 <xref rid="bb0045" ref-type="bibr">9</xref>].
</p>
